Brief international cognitive assessment for MS ( BICAMS ) and NEDA maintenance in MS patients: A 2‐year follow‐up longitudinal study
European Journal of Neurology · 2025
DOI: 10.1111/ene.70007 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von E Leveraro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca, Fondazione Italiana Sclerosi Multipla, Ministero della Salute.
Abstract (Originalsprache)
Background
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been validated in many cross‐sectional studies. However, longitudinal data on BICAMS subset trajectories and their correlation with disease activity during follow‐up are scarce.
Objectives
We aimed to (i) assess BICAMS changes in MS patients initiating high‐efficacy disease‐modifying‐treatments (DMTs), (ii) compare these changes based on maintenance of “no‐evidence‐of‐disease‐activity” (NEDA‐3) status over 24 months, and (iii) determine baseline clinical parameters predictive of cognitive changes.
Methods
We enrolled 101 MS patients (mean age:40,45 ± 11; Relapsing–Remitting‐MS:81%) initiating highly‐effective‐DMTs. Patients underwent Expanded Disability Status Scale (EDSS), BICAMS, and Hospital Anxiety and Depression Scale (HADS), at baseline and after 24 months. Regression‐based change index (RB‐CI) had been used for cognitive change evaluation over follow‐up.
Results
During follow‐up, 78 (77.3%) patients maintained NEDA‐3 status. Considering a 90% of confidence levels for RB‐CI, 12 (11.9%) improved at SDMT, 13 (12.9%) at CVLT‐II and 13 (12.9%) at BVMT‐R; while 7 (6.9%) were classified as worsened at SDMT, 11 (10.9%) at CVLT‐II and 8 (7.9%) at BVMT‐R. SDMT scores significantly improved at follow‐up for the entire group ( p = 0.003) and in patients maintaining NEDA‐3 ( p < 0.001). The multivariable regression model assessing the SDMT improvement ( n = 12; z = 1.65), was significant and explained 21% of the variance ( p = 0.038; Nagelkerke R 2 = 0.212). Lower EDSS proved to be an independent predictor of SDMT reliable improvement ( p = 0.027) in our sample.
Conclusions
Our findings showed that early disease activity control—especially in patients with low baseline disability—may yield significant benefits even in terms of cognitive performance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
ORCID-Profile: E Leveraro, M Cellerino, C Lapucci, D Boccia, M Inglese
Förderung
- Ministero dell'Università e della Ricerca
- Fondazione Italiana Sclerosi Multipla
- Ministero della Salute
Zitieren
APA
Leveraro, E., Cellerino, M., Lapucci, C., Dighero, M., Nasone, L., Sirito, T., Boccia, D., Cavalli, N., Bavestrello, G., Uccelli, A., Boffa, G., & Inglese, M. (2025). Brief international cognitive assessment for MS ( BICAMS ) and NEDA maintenance in MS patients: A 2‐year follow‐up longitudinal study. European Journal of Neurology. https://doi.org/10.1111/ene.70007
Vancouver
Leveraro E, Cellerino M, Lapucci C, Dighero M, Nasone L, Sirito T, et al. Brief international cognitive assessment for MS ( BICAMS ) and NEDA maintenance in MS patients: A 2‐year follow‐up longitudinal study. European Journal of Neurology. 2025. doi:10.1111/ene.70007
BibTeX
@article{Leveraro2025,
author = {Leveraro, E and Cellerino, M and Lapucci, C and Dighero, M and Nasone, L and Sirito, T and Boccia, D and Cavalli, N and Bavestrello, G and Uccelli, A and Boffa, G and Inglese, M},
title = {Brief international cognitive assessment for MS ( BICAMS ) and NEDA maintenance in MS patients: A 2‐year follow‐up longitudinal study},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70007}
}
EUVIMED